Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

Guideline Recommendations forEGFRMutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group

Shim, H. S., Chung, J.-H., Kim, L., Chang, S. H., Kim, W. S., Lee, G. K., Jung, S., & Jang, S. J. (2013) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2013.47.2.100 · Cited by 14

Analysis of BIM ( BCL ‐2 like 11 gene) deletion polymorphism in C hinese non‐small cell lung cancer patients

Zhong, J., Li, Z., Zhao, J., Duan, J., Bai, H., An, T., Yang, X., & Wang, J. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12119 · Cited by 14

Etoposide-Cisplatin Alternating with Vinorelbine-Cisplatin Versus Etoposide-Cisplatin Alone in Patients with Extensive Disease Combined with Small Cell Lung Cancer

Zhang, J., Qi, H., Zheng, H., Chen, M., Zhu, J., Xie, H., Ni, J., Xu, J., & Zhou, C. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.10.4159 · Cited by 13

Malignant pleural effusion cell blocks are substitutes for tissue in EML 4‐ ALK rearrangement detection in patients with advanced non‐small‐cell lung cancer

Zhong, J., Li, X., Bai, H., Zhao, J., Wang, Z., Duan, J., An, T., Wu, M., Wang, Y., Wang, S., et al. (2016) · Cytopathology · doi:10.1111/cyt.12322 · Cited by 13

Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients

Kim, M., Kim, M., Kim, S. J., An, S., Park, H., Park, H., Lee, J. H., Song, K.-B., Hwang, D. W., Chang, S., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0416-8 · Cited by 14

Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)

Tseng, Y.-H., Hung, H.-Y., Sung, Y.-C., Tseng, Y., Lee, Y.-C., Whang‐Peng, J., & Chen, Y.-M. (2015) · Journal of Chemotherapy · doi:10.1179/1973947815y.0000000027 · Cited by 13

Advances in personalized therapy for lung cancer

Kim, E. S., & Pandya, K. J. (2013) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2013.826645 · Cited by 13

Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment

Kuiper, J. L., Heideman, D. A. M., Würdinger, T., Grünberg, K., Groen, H. J. M., & Smit, E. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.008 · Cited by 13

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases

Qi, H., Hou, Y., Zheng, Z., Zheng, M., Qiao, Q., Wang, Z.-H., Sun, X., & Xing, L. (2024) · BMC Cancer · doi:10.1186/s12885-024-12121-z · Cited by 12

Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations

Zheng, Z., Jin, X., Lin, B., Su, H., Chen, H., Fei, S., Zhao, L., Deng, X., Xie, D., & Xie, C. (2017) · Journal of Cancer · doi:10.7150/jca.16959 · Cited by 12

A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer

Jiang, M.-Q., Zhang, X., Chen, Y., Chen, P., Guo, X., Ma, L., Gao, Q., Mei, W.-Q., Zhang, J.-F., & Zheng, J.-J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.780186 · Cited by 12

Influence of chemotherapy on EGFR mutation status.

Luo, Y., & Chen, Y. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.12 · Cited by 12

Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R

Deng, W., Lei, Y., Liu, S. M., Yang, J., Tu, H., Yan, H., & Wu, Y.-L. L. C. (2016) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2016.03.08 · Cited by 10

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies

Fu, S., Zhao, J., Bai, H., Duan, J., Wang, Z., An, T., & Wang, J. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12291 · Cited by 11

A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease

Mariano, C. J., Bosdet, I., Karsan, A., Ionescu, D. N., Murray, N., Laskin, J. J., Zhai, Y., Melosky, B. L., Sun, S. B., & Ho, C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.007 · Cited by 10

Using Vision Transformer for high robustness and generalization in predicting EGFR mutation status in lung adenocarcinoma

Weng, L., Xu, Y., Chen, Y., Chen, C., Qian, Q., Pan, J., & Su, H. W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03366-4 · Cited by 11

Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Cui, S., Xiong, L., Lou, Y., Shi, H., Gu, A., Zhao, Y., Chu, T., Wang, H., Zhang, W., Dong, L., et al. (2016) · PubMed Central · doi:10.3978/j.issn.2072-1439.2016.01.12 · Cited by 10

Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer

Kang, H. J., Hwangbo, B., Lee, J. S., Kim, M. S., Lee, J. M., & Lee, G.-K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163652 · Cited by 10

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer

Tran, V. T., Phan, T. T., Nguyen, S. T., Tran, B., Ho, T. T., Pho, S. P., Nguyen, T. B., Pham, T. T. B., Le, A. T., Le-Thuong, V., et al. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05209-9 · Cited by 11

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy

van der Mijn, J. C., Eng, K., Chandra, P., Fernandez, E. M., Ramazanoglu, S., Sigaras, A., Oromendia, C., Gudas, L. J., Tagawa, S. T., Nanus, D. M., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13204 · Cited by 10

Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip

Ren, L., Zhou, M., Li, J., Wang, Z., Zhang, W., Yue, C., Ma, Y., Peng, H., Wei, Z., & Hu, Z. (2017) · Nano-Micro Letters · doi:10.1007/s40820-017-0168-y · Cited by 10

Change of SPARC expression after chemotherapy in gastric cancer.

Gao, Y.-Y., Han, R.-B., Wang, X., Ge, S., Li, H.-L., Deng, T., Liu, R., Bai, M., Zhou, L.-K., Zhang, X.-Y., et al. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.0023 · Cited by 9

EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy.

Bar, J., Urban, D., Borshtein, R., Nechushtan, H., & Onn, A. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.12.03 · Cited by 9

Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors

Zheng, Z., Xie, D., Su, H., Lin, B., Zhao, L., Deng, X., Chen, H., Fei, S., Jin, X., & Xie, C. (2017) · Tumor Biology · doi:10.1177/1010428317706211 · Cited by 9

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts

Cui, J., Zhang, Y., Su, D., Li, T., & Li, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12818 · Cited by 9

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC

Zhang, L., Wu, X., Wenhua, L., Xue, H., zhong, L., hongyun, Z., yan, H., Wenfeng, F., Zhao, Y., Wu, J., et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s51887 · Cited by 9

Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer

Zhuo, M., Bai, H., Wang, Z., Duan, J., An, T., Wu, M., Zhao, J., Wang, Y., Wang, S., & Wang, J. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.359 · Cited by 9

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

Jakobsen, J. N., Santoni‐Rugiu, E., & Sørensen, J. B. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2315-6 · Cited by 8

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers

Zhong, W., Su, J., Xu, F., Zhai, H.-R., Zhang, X., Yang, X., Chen, Z., Chen, Z., Li, W., Dong, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.007 · Cited by 8

Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

Yamane, H., Ochi, Yasugi, Tabayashi, Yamagishi, Monobe, Hisamoto, Kiura, K., & Takigawa (2013) · OncoTargets and Therapy · doi:10.2147/ott.s41797 · Cited by 8

Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling

Li, R., Zhou, M., Yue, C., Zhang, W., Ma, Y., Peng, H., Hu, Z., & Wei, Z. (2018) · Lab on a Chip · doi:10.1039/c7lc00924k · Cited by 8

Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer

Wang, S., An, T., Duan, J., Zhang, L., Wu, M., Zhou, Q., Chen, J., Zhuo, M., Yang, L., Wang, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051021 · Cited by 7

Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer HarboringEGFRMutation

Jang, S. H. (2014) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2014.76.1.8 · Cited by 7

Individualized treatment of NSCLC: From research to clinical practice

Wang, Y., Liu, Z., Zhao, L., Du, C., Xi, X. M., Mi, Y. L., Peng, Y., Li, W. G., Cheng, F., Zhang, X. R., et al. (2013) · Neoplasma · doi:10.4149/neo_2013_070 · Cited by 7

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma

He, Y., Wang, Y., Zhang, S., Ren, S., Li, J., & Zhou, C. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.06.009 · Cited by 6

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Karachaliou, N., & Rosell, R. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s50671 · Cited by 6

Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making

Theocharopoulos, C., Machairas, N., Ziogas, I. A., Mungo, B., Chiaro, M. D., Glantzounis, G. K., Schulick, R. D., & Sotiropoulos, G. C. (2025) · Cancers · doi:10.3390/cancers18010094 · Cited by 5

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy

Gautschi, O. P., Stadelmann, C., Aebersold, F., König, K., Büttner, R., Heukamp, L. C., Betticher, D. C., Baumann, C. K., Buser, K., Calderoni, A., et al. (2015) · Oncology Research and Treatment · doi:10.1159/000441367 · Cited by 5

Targeted Therapy Management in NSCLC Patients Using Cytology: Experience from a Tertiary Care Cancer Center

Veldore, V. H., Patil, S. G., Prabhudesai, S. A., Satheesh, C. T., Shashidhara, H. P., Krishnamoorthy, N., Hazarika, D., Tejaswi, R., Prabhudev, A., Naik, R., et al. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0180-1 · Cited by 5

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients

Chen, J., Li, H., Pang, R., & Huang, J. M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s127498 · Cited by 5

Clinical characteristics and prognostic value of EGFR mutation in stage I lung adenocarcinoma with spread through air spaces after surgical resection

Mao-Gang, G. A. O., Wang, S., Han, K.-H., Xie, S.-N., & Liu, Q. (2022) · Neoplasma · doi:10.4149/neo_2022_220619n649 · Cited by 5

Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy

Su, D. G., Dhiman, A., Bansal, V. V., Zha, Y., Shergill, A. P., Polite, B. N., Alpert, L., Turaga, K. K., & Eng, O. S. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00149 · Cited by 5

Can EGFR mutation status evolve with chemotherapy?

Kim, E. S., Stewart, D. J., & Khorana, A. A. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.09 · Cited by 5

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China

Cao, W., Gao, Y. L., & Wang, X. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0628-6 · Cited by 5

CNAPS in Therapy Monitoring

Holdenrieder, S. (2014) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-017-9168-7_12 · Cited by 5

EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Bar, J., Cyjon, A., Flex, D., Sorotsky, H. G., Biran, H., Dudnik, J., Peylan‐Ramu, N., Peled, N., Nechushtan, H., Gips, M., et al. (2014) · Lung · doi:10.1007/s00408-014-9604-7 · Cited by 5

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas

Simon, E., Bick, T., Sarji, S., Shentzer, T., Prinz, E., Yehiam, L., Sabo, E., Ben‐Izhak, O., & Hershkovitz, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17399 · Cited by 5

Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case

Isaka, T., Yokose, T., Ito, H., Imamura, N., Watanabe, M., Imai, K., Nishii, T., Yamada, K., Nakayama, H., & Masuda, M. (2014) · Surgery Today · doi:10.1007/s00595-014-1077-z · Cited by 4

Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment

Wu, W.-S., Wu, C., Lai, S., Chiu, C., Shih, J.-F., Lee, Y., & Chen, Y. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000096 · Cited by 4

Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer

Scagliotti, G. V., & Vokes, E. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00051-2 · Cited by 4

Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations

Zhang, H., Bai, H., Yang, X., Zhong, J., An, T., Zhao, J., & Wang, J. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12266 · Cited by 4

Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute.

Wang, W., Tang, Y., Li, J., Zhang, Y., Zou, Y., & Su, X. (2018) · PubMed Central · Cited by 4

Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report

Ma, C., Wang, S., Mu, N., Li, J., Liu, M., Li, L., & Jiang, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01635 · Cited by 3

Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Genome biology · doi:10.1186/s13059-024-03201-1 · Cited by 3

Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

Jakobsen, J. N., Santoni‐Rugiu, E., & Sørensen, J. B. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2329-0 · Cited by 3

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib

Yang, T., Xu, R., Yan, B., Li, F., & Liu, H. (2018) · Medicine · doi:10.1097/md.0000000000013797 · Cited by 3

Retreatment with icotinib in a patient with metastatic lung adenocarcinoma

Sun, X., & Zheng, Y. (2013) · Tumori Journal · doi:10.1177/030089161309900331 · Cited by 3

Field carcinogenesis and biological significance of the potential of the bystander effect: carcinogenesis, therapeutic response, and tissue regeneration

Kuwano, H., Yokobori, T., Miyazaki, T., Sohda, M., Yoshida, T., Azuma, Y., Tatsuki, H., Ubukata, Y., Nakazawa, N., Kuriyama, K., et al. (2022) · Surgery Today · doi:10.1007/s00595-022-02524-5 · Cited by 4

Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

Alrifai, D., Forster, M. D., & Janes, S. M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.11.13 · Cited by 3

Lung cancer patients

Gemine, R. E., Haider, S. A., Ravara, S., & Lewis, K. E. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10012220 · Cited by 3

Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients

Holdenrieder, S. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42044-8_11 · Cited by 3

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Liu, Y., Hao, X., Hu, X., Li, J., Wang, Y., Wang, H., Xing, P., Li, W., Ying, J., Han, X., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12596 · Cited by 3

Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology

Sakashita, S., Shiba‐Ishii, A., Murata, Y., Sekimoto, R., Minami, Y., Sato, Y., & Noguchi, M. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.05.016 · Cited by 3

Rare sequential EGFR and ALK mutations in non‑small cell lung cancer: A case report and literature review

Nguyen, V. H., Do, C., Tran, B. X., & Trinh, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15144 · Cited by 2

Artificial intelligence in cancer research and precision medicine

Corti, C., Cobanaj, M., Criscitiello, C., & Curigliano, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13671-9.00005-3 · Cited by 3

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report

SUN, Q., WU, J.-Y., & Jiao, S. (2014) · Oncology Letters · doi:10.3892/ol.2014.2468 · Cited by 2

A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report

Shiroyama, T., Tamiya, M., Hayama, M., Nishihara, T., Nishida, T., Tanaka, A., Morishita, N., Suzuki, H., Okamoto, N., Kawahara, K., et al. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.03.43 · Cited by 2

Mining tumor and surrounding tissue information using artificial intelligence to predict responses to EGFR-targeted therapies and immunotherapy in lung cancer: a multicenter attribution analysis

Zhang, X.-P., He, Y., Rao, T., Qiu, X.-T., Lai, Q., Zhang, Y.-C., & Zhang, G. (2025) · La radiologia medica · doi:10.1007/s11547-025-02077-w · Cited by 2

[Fourth-line and beyond therapy in advanced non-small cell lung cancer: a retrospective analysis].

Wang, X., Huang, M., Ren, L. M., Xu, Y., Li, L., Hou, M., Wang, J., Peng, F., Zhu, J., Wang, Y., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.12.03 · Cited by 1

Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer

Zimmermann, S., & Peters, S. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.058 · Cited by 1

Drifting EGFR mutation.

Noro, R., & Yamada, T. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.08 · Cited by 1

Zirkulierende Nukleinsäuren – ein neues Universum in der laboratoriumsmedizinischen Diagnostik

Neumaier, M. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0053 · Cited by 1

Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma

Özgü, E., Tokat, Ü. M., Adibi, A., Bilgiç, Ş. N., Aydın, E., Tutar, O., & Demiray, M. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00652 · Cited by 1

Epidermal Growth Factor Receptor Mutations detection by Mutant Specific Immunohistochemistry in North Indian Lung Cancer population

Gaur, P., Bhattacharya, S., Kant, S., Kushwaha, R., Agarwal, J., & Pathak, A. K. (2017) · International Journal of Research and Development in Pharmacy and Life Sciences · doi:10.21276/ijrdpl.2278-0238.2017.6(6).2796-2799 · Cited by 1

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Shi, X., Huang, F., Chen, A. M., Wu, Z., Huang, Q., Liang, Y., Zhou, Q., Mo, H., Li, X., & Zhang, J. (2017) · Open Journal of Genetics · doi:10.4236/ojgen.2017.74010 · Cited by 1

[Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].

Su, F., Zheng, K., Fu, Y., Wu, Q., Tang, Y., Wang, W., & Jiang, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.05.06 · Cited by 1

[Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients].

Li, H., Yan, S., Liu, X., Liu, Y., Ma, L., Wang, Y., Liu, Y., & Cheng, Y. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.03 · Cited by 1

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report

Ueda, M., Namba, M., Tokumo, K., Senoo, T., Okamoto, W., Yamauchi, M., Hattori, N., & Sugiyama, K. (2021) · Case Reports in Oncology · doi:10.1159/000518246 · Cited by 1

Epidermal growth factor receptor mutation in adenosquamous carcinoma: A step forward

Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.05.008 · Cited by 1

EGFR and KRAS mutation coexistence in lung adenocarcinomas

de Sousa, V. M. L., Silva, M. R., Alarcão, A., d’Aguiar, M. J., Ferreira, T., & Carvalho, L. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17629/www.diagnosticpathology.eu-2015-1:13

Strategy on Patients with EGFR Mutation

Früh, M., Zhou, Q. H., Leung, L. K. S., & Mok, T. S. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_9

Heterogeneity of EGFR mutations in a patient treated with gefitinib as neo-adjuvant chemotherapy

Mizoguchi, K., Nakamura, Y., Abe, K., Takemoto, S., Motoshima, K., Ogawara, D., Nakatomi, K., Fukuda, M., Fukuoka, J., & Kohno, S. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.08.002

Circulating Cell-Free DNA: A Potential Biomarker in Lung Cancer

Taylor, F., Teare, M. D., Cox, A., & Woll, P. J. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.47

Coexistence of an EGFR Mutation and an ALK Rearrangement in a Patient with Lung Adenocarcinoma: a Case Report

Kim, M. A., Kang, J. H., Kim, I.-H., Kim, T. J., Kim, S. J., Sung, S. W., & Huo, S. M. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.90.1.72

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and

Shen, L., & Zheng, D. (2014)

P3.01-018 Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis

Wang, H., Zhang, M., Jie, M., Zhang, G., Yan, X., Zhang, X., & Ma, Z. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1459

Lung adenocarcinoma patient progression with gastrointestinal metastasis response to subsequent tyrosine kinase inhibitors (TKIs) from re-biopsy of new occurring driver gene mutation

Zhou, C., Yan, B., Zeng, L., Xiong, Y., Liu, L., Yang, N., & Zhang, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.97

Develop Micro/Nano Technologies for Cancer Diagnosis

Zheng, S. (2021) · IEEE International Conference on Micro Electro Mechanical Systems (MEMS) · doi:10.1109/mems51782.2021.9375338

Acquired ROS1 fusion and iruplinalkib response in advanced NSCLC after multiple lines of systematic therapy: a case report

Liu, J., Jiao, Z., Zhou, J., Yuan, Y., Li, Q., Zhou, W., Zhang, S., & Yang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1571512

Additional file 4 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915426

Additional file 2 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915417

Additional file 5 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.26690773

Additional file 8 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.26690782

Additional file 4 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.26690770

Additional file 1 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915414

Additional file 3 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915420

Additional file 1 of Transfer learning–based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in lung adenocarcinoma

邵小南, Ge, X., Gao, J., Niu, R., Shi, Y., Shao, X., Jiang, Z., Li, R., & Wang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25341110

Additional file 3 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.26690767

Additional file 1 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.25374702

Additional file 7 of Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution

Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Figshare · doi:10.6084/m9.figshare.26690779

Effect of chemotherapy on EGFR mutation status in Chinese non-small cell lung cancer patients.

Wang, J., Bai, H., Zhao, J., Wang, Z., Zhuo, M., Wu, M., Duan, J., & Wang, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e18031 · Cited by 2

Influence of chemotherapy on EGFR mutation status.

Luo, Y., & Chen, Y. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.12 · Cited by 12

Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

Wang, J., Chen, K., Bai, H., Zhao, J., Wang, Z., Zhuo, M., An, T., Duan, J., Yang, L., Wu, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7031 · Cited by 4

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Shi, X., Huang, F., Chen, A. M., Wu, Z., Huang, Q., Liang, Y., Zhou, Q., Mo, H., Li, X., & Zhang, J. (2017) · Open Journal of Genetics · doi:10.4236/ojgen.2017.74010 · Cited by 1

Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

Hua, B., Zhao, J., Wang, S. H., Yang, L., Duan, J. C., Wu, M. N., & Wang, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8099 · Cited by 1